As the commercialization landscape grows more complex, pharmaceutical manufacturers are being challenged to scale innovation while maintaining executional rigor. Rising expectations around access, data integration, and AI adoption are forcing organizations to rethink how they operate across the product lifecycle.
In a recent Q&A with Pharmaceutical Executive, Mark Thierer, CEO of EVERSANA, shared how industry conversations have shifted from strategy to execution — and what it takes to deliver results at scale.
Read the full Q&A in Pharmaceutical Executive
From Strategy to Execution
According to Thierer, the industry has reached an inflection point. Conversations once centered on uncertainty and direction are now focused on implementation.
Manufacturers are asking a different question: not what should we do? but how do we make it work at scale? This shift is driving demand for integrated approaches that reduce handoffs, improve visibility, and connect strategy to real‑world performance.
Why Integrated Models Are Gaining Ground
Fragmented vendor ecosystems are giving way to more connected operating models. Manufacturers are increasingly adopting integrated frameworks that align data, strategy, and execution under a single structure.
These models enable:
- Faster launch readiness
- More coordinated patient engagement
- Greater consistency across the lifecycle
Flexibility is key. Organizations need solutions that scale with market dynamics without requiring infrastructure to be rebuilt at each stage.
The Role of Data and AI
Data has evolved from a reporting tool into a strategic engine. Today, it enables earlier, smarter decisions by connecting insights across commercial, medical, access, and patient services.
AI is accelerating this shift. Rather than being layered on top, AI is increasingly embedded into commercialization workflows — driving orchestration across data, content, and channels.
What Comes Next
For Thierer, the path forward is clear: organizations that succeed will be those that connect innovation with execution while maintaining focus on patient access and outcomes.
That balance — agility with operational rigor — is becoming the new standard for commercialization.
Explore EVERSANA’s COMPLETE Commercialization model
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…